350 related articles for article (PubMed ID: 36857860)
21. SARS-CoV2 variant-specific replicating RNA vaccines protect from disease following challenge with heterologous variants of concern.
Hawman DW; Meade-White K; Archer J; Leventhal SS; Wilson D; Shaia C; Randall S; Khandhar AP; Krieger K; Hsiang TY; Gale M; Berglund P; Fuller DH; Feldmann H; Erasmus JH
Elife; 2022 Feb; 11():. PubMed ID: 35191378
[TBL] [Abstract][Full Text] [Related]
22. Reduced SARS-CoV-2 mRNA vaccine immunogenicity and protection in mice with diet-induced obesity and insulin resistance.
O'Meara TR; Nanishi E; McGrath ME; Barman S; Dong D; Dillen C; Menon M; Seo HS; Dhe-Paganon S; Ernst RK; Levy O; Frieman MB; Dowling DJ
J Allergy Clin Immunol; 2023 Nov; 152(5):1107-1120.e6. PubMed ID: 37595760
[TBL] [Abstract][Full Text] [Related]
23. SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022.
Canaday DH; Oyebanji OA; White EM; Bosch J; Nugent C; Vishnepolskiy I; Abul Y; Didion EM; Paxitzis A; Sundheimer N; Ragavapuram V; Wilk D; Keresztesy D; Cao Y; St Denis K; McConeghy KW; McDonald LC; Jernigan JA; Mylonakis E; Wilson BM; King CL; Balazs AB; Gravenstein S
MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(4):100-106. PubMed ID: 36701254
[TBL] [Abstract][Full Text] [Related]
24. Intranasal administration of a single dose of MVA-based vaccine candidates against COVID-19 induced local and systemic immune responses and protects mice from a lethal SARS-CoV-2 infection.
Pérez P; Astorgano D; Albericio G; Flores S; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
Front Immunol; 2022; 13():995235. PubMed ID: 36172368
[TBL] [Abstract][Full Text] [Related]
25. Can Individuals with Suboptimal Antibody Responses to Conventional Antiviral Vaccines Acquire Adequate Antibodies from SARS-CoV-2 mRNA Vaccination?
Ogura W; Ohtsuka K; Matsuura S; Okuyama T; Matsushima S; Yamasaki S; Miyagi H; Sekiguchi K; Ohnishi H; Watanabe T
Viruses; 2022 May; 14(5):. PubMed ID: 35632698
[TBL] [Abstract][Full Text] [Related]
26. Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark.
Hansen CH; Friis NU; Bager P; Stegger M; Fonager J; Fomsgaard A; Gram MA; Christiansen LE; Ethelberg S; Legarth R; Krause TG; Ullum H; Valentiner-Branth P
Lancet Infect Dis; 2023 Feb; 23(2):167-176. PubMed ID: 36270311
[TBL] [Abstract][Full Text] [Related]
27. Effect of vaccine booster, vaccine type, and hybrid immunity on humoral and cellular immunity against SARS-CoV-2 ancestral strain and Omicron variant sublineages BA.2 and BA.5 among older adults with comorbidities: a cross sectional study.
Fong CH; Zhang X; Chen LL; Poon RW; Chan BP; Zhao Y; Wong CK; Chan KH; Yuen KY; Hung IF; Yuen JKY; To KK
EBioMedicine; 2023 Feb; 88():104446. PubMed ID: 36706582
[TBL] [Abstract][Full Text] [Related]
28. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.
Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P
Front Immunol; 2022; 13():816389. PubMed ID: 35464418
[TBL] [Abstract][Full Text] [Related]
29. mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant.
Nanishi E; McGrath ME; O'Meara TR; Barman S; Yu J; Wan H; Dillen CA; Menon M; Seo HS; Song K; Xu AZ; Sebastian L; Brook B; Bosco AN; Borriello F; Ernst RK; Barouch DH; Dhe-Paganon S; Levy O; Frieman MB; Dowling DJ
Commun Biol; 2022 Aug; 5(1):790. PubMed ID: 35933439
[TBL] [Abstract][Full Text] [Related]
30. Vaccine-induced protection against SARS-CoV-2 requires IFN-γ-driven cellular immune response.
Wang X; Yuen TT; Dou Y; Hu J; Li R; Zeng Z; Lin X; Gong H; Chan CH; Yoon C; Shuai H; Ho DT; Hung IF; Zhang BZ; Chu H; Huang JD
Nat Commun; 2023 Jun; 14(1):3440. PubMed ID: 37301910
[TBL] [Abstract][Full Text] [Related]
31. Omicron BA.5 Neutralization among Vaccine-Boosted Persons with Prior Omicron BA.1/BA.2 Infections.
Pedersen RM; Bang LL; Tornby DS; Madsen LW; Holm DK; Sydenham TV; Johansen IS; Jensen TG; Justesen US; Andersen TE
Emerg Infect Dis; 2022 Dec; 28(12):2575-2577. PubMed ID: 36347270
[TBL] [Abstract][Full Text] [Related]
32. Boosting of serum neutralizing activity against the Omicron variant among recovered COVID-19 patients by BNT162b2 and CoronaVac vaccines.
Lu L; Chen LL; Zhang RR; Tsang OT; Chan JM; Tam AR; Leung WS; Chik TS; Lau DP; Choi CY; Fong CH; Cai JP; Tsoi HW; Choi CY; Zhang X; Abdullah SMU; Chan BP; Chan KH; Yuen KY; Hung IF; To KK
EBioMedicine; 2022 May; 79():103986. PubMed ID: 35398786
[TBL] [Abstract][Full Text] [Related]
33. Comparable humoral and cellular immunity against Omicron variant BA.4/5 of once-boosted BA.1/2 convalescents and twice-boosted COVID-19-naïve individuals.
Kang CK; Kim MG; Park SW; Kim YW; Lee CM; Choe PG; Park WB; Kim NJ; Kim M; Lee S; Kim IS; Lee CH; Shin HM; Kim HR; Oh MD
J Med Virol; 2023 Feb; 95(2):e28558. PubMed ID: 36755360
[TBL] [Abstract][Full Text] [Related]
34. Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection.
Americo JL; Cotter CA; Earl PL; Liu R; Moss B
Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2202069119. PubMed ID: 35679343
[TBL] [Abstract][Full Text] [Related]
35. Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients.
Trougakos IP; Terpos E; Zirou C; Sklirou AD; Apostolakou F; Gumeni S; Charitaki I; Papanagnou ED; Bagratuni T; Liacos CI; Scorilas A; Korompoki E; Papassotiriou I; Kastritis E; Dimopoulos MA
BMC Med; 2021 Aug; 19(1):208. PubMed ID: 34420521
[TBL] [Abstract][Full Text] [Related]
36. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
[TBL] [Abstract][Full Text] [Related]
37. Omicron-specific mRNA vaccine induced cross-protective immunity against ancestral SARS-CoV-2 infection with low neutralizing antibodies.
Shen KY; Yang CH; Chen CT; Ho HM; Chiu FF; Huang CY; Liao HC; Hsu CW; Yu GY; Liao CL; Chen HW; Huang MH; Liu SJ
J Med Virol; 2023 Jan; 95(1):e28370. PubMed ID: 36458553
[TBL] [Abstract][Full Text] [Related]
38. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
[TBL] [Abstract][Full Text] [Related]
39. Design and preclinical evaluation of a universal SARS-CoV-2 mRNA vaccine.
Qin J; Jeon JH; Xu J; Langston LK; Marasini R; Mou S; Montoya B; Melo-Silva CR; Jeon HJ; Zhu T; Sigal LJ; Xu R; Zhu H
Front Immunol; 2023; 14():1126392. PubMed ID: 37033973
[TBL] [Abstract][Full Text] [Related]
40. Host immune responses associated with SARS-CoV-2 Omicron infection result in protection or pathology during reinfection depending on mouse genetic background.
Singh G; Warang P; García-Bernalt Diego J; Chang L; Bykov Y; Singh S; Pache L; Cuadrado-Castano S; Webb B; Garcia-Sastre A; Schotsaert M
Res Sq; 2023 Nov; ():. PubMed ID: 38077015
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
